BI-248.622

Study Sponsor: Boehringer Ingelheim

Study Title

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

Medicine or Vaccine (generic name)

pramipexole

Sponsor Identification Number

248.622

Trial Registry Identification Number(#'s)

NCT00402233

Medical Condition

Parkinson Disease

Phase

Phase 4

Link to study details on the BI Clinical Study Register

http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/ct2/show/NCT00402233?term=248.622&rank=1

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

November 2014